Skip to main content
Erschienen in: Current Treatment Options in Oncology 9/2016

01.09.2016 | Skin Cancer (BY Kwong, Section Editor)

The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma

verfasst von: Kim Margolin, M.D.

Erschienen in: Current Treatment Options in Oncology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Opinion Statement

Advanced melanoma, rarely diagnosed at the time of primary melanoma excision but most often occurring later via lymphatic or hematogenous dissemination, is the cause of death for approximately 10,000 people in the USA each year, with the rate of incidence and death increasing yearly. Its causes are multifactorial and depend in large part on solar ultraviolet damage to DNA as well as underlying genetic predisposition. Cutaneous melanoma is the most common, but other subsets of importance are mucosal and uveal primaries, with different biology and treatment considerations. Mutational oncogenic “drivers” may be targeted with chronically administered, oral kinase inhibitors, currently consisting of the mitogen-activated protein kinase (MAPK) inhibitor combinations of BRAF plus MEK-targeted drugs. These agents work quickly to relieve symptoms and induce remissions but generally have limited durations of disease control. Immunotherapies include the immune checkpoint inhibitors that block CTLA4 or PD-1-negative immune signaling as well as interleukin-2, a cytokine that stimulates T lymphocytes and natural killer cells. A combination of CTLA4 plus PD-1 blockade has the highest activity ever reported for metastatic melanoma, at the cost of high autoimmune-like toxicities. However, immunotherapies of this type may provide durable responses and even cure a subset of patients. Thus, these immunotherapeutic agents are recommended as first-line therapy for most patients with advanced melanoma. Patients with rapidly progressive, symptomatic melanoma whose tumor carries a BRAF mutation may benefit more from initial therapy with combined MAPK inhibitors.
Literatur
1.
2.
Zurück zum Zitat Cancer Facts & Figs. 2015 American Cancer Society (cancer.org) Cancer Facts & Figs. 2015 American Cancer Society (cancer.org)
3.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
4.
Zurück zum Zitat Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.CrossRefPubMed Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.CrossRefPubMed
5.•
Zurück zum Zitat Johnson DB, Menzies AM, Zimmer L, et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015;51:2792–9. Resistance mechanisms to the current only targetable oncogenic driver mutation develop early and often, and increased understanding of their molecular biology and relative representation informs new studies of novel agents to pre-empt or overcome resistanceCrossRefPubMed Johnson DB, Menzies AM, Zimmer L, et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015;51:2792–9. Resistance mechanisms to the current only targetable oncogenic driver mutation develop early and often, and increased understanding of their molecular biology and relative representation informs new studies of novel agents to pre-empt or overcome resistanceCrossRefPubMed
6.
Zurück zum Zitat Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480:387–90.CrossRefPubMedPubMedCentral Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480:387–90.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.CrossRefPubMedPubMedCentral Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.CrossRefPubMed Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.CrossRefPubMed
9.•
Zurück zum Zitat Hagen B. Managing side effects of vemurafenib therapy for advanced melanoma. J Adv Pract Oncol. 2014;5:400–10. As new drugs with novel mechanism of action present new challenges for toxicity recognition and management, it is important to have references that provide evidence- and experience-based recommendationsPubMedPubMedCentral Hagen B. Managing side effects of vemurafenib therapy for advanced melanoma. J Adv Pract Oncol. 2014;5:400–10. As new drugs with novel mechanism of action present new challenges for toxicity recognition and management, it is important to have references that provide evidence- and experience-based recommendationsPubMedPubMedCentral
10.
Zurück zum Zitat Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–14.CrossRefPubMed Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–14.CrossRefPubMed
11.••
Zurück zum Zitat Long GV, Stroyakovsky D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–88. The first of several papers to demonstrate improvement in all outcomes for combination vertical MAPK inhibition and to confirm and expand medical knowledge regarding the spectrum of toxicities and side effectsCrossRefPubMed Long GV, Stroyakovsky D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–88. The first of several papers to demonstrate improvement in all outcomes for combination vertical MAPK inhibition and to confirm and expand medical knowledge regarding the spectrum of toxicities and side effectsCrossRefPubMed
12.•
Zurück zum Zitat Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9. Complements the information reported in reference 12CrossRefPubMed Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9. Complements the information reported in reference 12CrossRefPubMed
13.••
Zurück zum Zitat Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–76. The first phase III data and support of the novel combination of vemurafenib and cobimetinib as an alternative to dabrafenib and trametinibCrossRefPubMed Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–76. The first phase III data and support of the novel combination of vemurafenib and cobimetinib as an alternative to dabrafenib and trametinibCrossRefPubMed
14.
Zurück zum Zitat Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32.CrossRefPubMed Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32.CrossRefPubMed
15.•
Zurück zum Zitat Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30. First demonstration of nivolumab activity in melanoma and its safety in a randomized trial against chemotherapy for untreated, BRAF wild-type metastatic melanomaCrossRefPubMed Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30. First demonstration of nivolumab activity in melanoma and its safety in a randomized trial against chemotherapy for untreated, BRAF wild-type metastatic melanomaCrossRefPubMed
16.
17.•
Zurück zum Zitat McNeal AS, Liu K, Nakhate V, et al. CDKN2B loss promotes progression from benign melanocytic nevus to melanoma. Cancer Discov. 2015;5:1072–85. A critical molecular explanation for the transition from BRAF v600-mutated benign/senescent nevi to invasive melanomaCrossRefPubMedPubMedCentral McNeal AS, Liu K, Nakhate V, et al. CDKN2B loss promotes progression from benign melanocytic nevus to melanoma. Cancer Discov. 2015;5:1072–85. A critical molecular explanation for the transition from BRAF v600-mutated benign/senescent nevi to invasive melanomaCrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Menzies AM, Haydu LE, Visintin I, et al. Distinguishing clinicopathologic features of patients with v600E and v600K mutations. Clin Cancer Res. 2012;18:32–49. Menzies AM, Haydu LE, Visintin I, et al. Distinguishing clinicopathologic features of patients with v600E and v600K mutations. Clin Cancer Res. 2012;18:32–49.
19.
Zurück zum Zitat Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015;526:583–6.CrossRefPubMed Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015;526:583–6.CrossRefPubMed
20.•
Zurück zum Zitat Nissan MH, Pratilas CA, Jones AM, et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 2015;74:2340–50 . Discovery of a new driver oncogene with known signaling pathways that accounts for many of the melanomas not dependent on BRAF or NRAS mutationCrossRef Nissan MH, Pratilas CA, Jones AM, et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 2015;74:2340–50 . Discovery of a new driver oncogene with known signaling pathways that accounts for many of the melanomas not dependent on BRAF or NRAS mutationCrossRef
21.
Zurück zum Zitat Renzani M, Alifrangis C, Perna D, et al. BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib. Pigment Cell Melanoma Res. 2014;28:117–9.CrossRef Renzani M, Alifrangis C, Perna D, et al. BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib. Pigment Cell Melanoma Res. 2014;28:117–9.CrossRef
22.•
Zurück zum Zitat Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311:2397–405. Proof of principle for the importance of MEK as a druggable target in the biology and therapy of uveal melanoma and confirmation of the extremely low benefit of chemotherapy in uveal melanomaCrossRefPubMedPubMedCentral Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311:2397–405. Proof of principle for the importance of MEK as a druggable target in the biology and therapy of uveal melanoma and confirmation of the extremely low benefit of chemotherapy in uveal melanomaCrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Cooper ZA, Reuben A, Austin-Breneman J, Wargo JA. Does it MEK a difference? Understanding immune effects of targeted therapy. Clin Cancer Res. 2015;21:3102–4.CrossRefPubMedPubMedCentral Cooper ZA, Reuben A, Austin-Breneman J, Wargo JA. Does it MEK a difference? Understanding immune effects of targeted therapy. Clin Cancer Res. 2015;21:3102–4.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Hu-Lieskovan S, Mok S, Homet Moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7:279ra41.CrossRefPubMedPubMedCentral Hu-Lieskovan S, Mok S, Homet Moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7:279ra41.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Niessner H, Forschner A, Klumpp B, et al. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med. 2013;2:76–85.CrossRefPubMedPubMedCentral Niessner H, Forschner A, Klumpp B, et al. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med. 2013;2:76–85.CrossRefPubMedPubMedCentral
26.•
Zurück zum Zitat Bucheit AD, Chen G, Siroy A, et al. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014;20:5527–36. One of several reports to demonstrate the association of PTEN functional loss with propensity to develop brain metastasisCrossRefPubMedPubMedCentral Bucheit AD, Chen G, Siroy A, et al. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014;20:5527–36. One of several reports to demonstrate the association of PTEN functional loss with propensity to develop brain metastasisCrossRefPubMedPubMedCentral
27.
28.
Zurück zum Zitat Wu X, Li J, Zhu M, Fletcher JA, Hodi FS. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol Cancer Ther. 2012;11:1905–14.CrossRefPubMedPubMedCentral Wu X, Li J, Zhu M, Fletcher JA, Hodi FS. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol Cancer Ther. 2012;11:1905–14.CrossRefPubMedPubMedCentral
29.••
Zurück zum Zitat Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–016. Review. The seminal report of a pooled cohort of patients who received high-dose IL-2 for metastatic melanoma and achieved durable remissions (approximately 7 %) and overall response rates (approximately 16–19 %) range, at the cost of substantial but reversible multisystem toxicityPubMed Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–016. Review. The seminal report of a pooled cohort of patients who received high-dose IL-2 for metastatic melanoma and achieved durable remissions (approximately 7 %) and overall response rates (approximately 16–19 %) range, at the cost of substantial but reversible multisystem toxicityPubMed
30.
Zurück zum Zitat Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–94.CrossRefPubMed Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–94.CrossRefPubMed
31.
Zurück zum Zitat Weber J, Kahler K, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–7.CrossRefPubMed Weber J, Kahler K, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–7.CrossRefPubMed
32.••
33.••
Zurück zum Zitat Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–9. These two sources are of great importance in demonstrating the critical role of the host microbiome (which can be manipulated) in determining not only the safety of therapy but also therapeutic outcomesCrossRefPubMedPubMedCentral Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–9. These two sources are of great importance in demonstrating the critical role of the host microbiome (which can be manipulated) in determining not only the safety of therapy but also therapeutic outcomesCrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003;33:2706–16.CrossRefPubMed Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003;33:2706–16.CrossRefPubMed
35.
Zurück zum Zitat Shin D, Garcia-Diaz A, Zaretsky J, et al. Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure. J Immunother Cancer. 2015;3(Suppl 2):P311.CrossRefPubMedCentral Shin D, Garcia-Diaz A, Zaretsky J, et al. Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure. J Immunother Cancer. 2015;3(Suppl 2):P311.CrossRefPubMedCentral
36.
Zurück zum Zitat Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–18.CrossRefPubMed Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–18.CrossRefPubMed
37.
Zurück zum Zitat Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.CrossRefPubMed Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.CrossRefPubMed
38.
Zurück zum Zitat Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.CrossRefPubMedPubMedCentral Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.CrossRefPubMedPubMedCentral
39.••
Zurück zum Zitat Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239–71. Review. A unique review that puts into perspective the molecular biology, etiologic factors and clinical associations in all subsets of melanomaCrossRefPubMedPubMedCentral Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239–71. Review. A unique review that puts into perspective the molecular biology, etiologic factors and clinical associations in all subsets of melanomaCrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Shain AH, Garrido M, Botton T, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet. 2015;47:1194–9.CrossRefPubMedPubMedCentral Shain AH, Garrido M, Botton T, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet. 2015;47:1194–9.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Reardon DA, Gokhale PC, Klein SR et al. (2015) Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res Reardon DA, Gokhale PC, Klein SR et al. (2015) Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res
42.•
Zurück zum Zitat Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33. The first clinical report of combination checkpoint blocking antibodies, with the highest reported benefit rate of any therapy for advanced melanoma and a very high rate of immune-related toxicitiesCrossRefPubMed Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33. The first clinical report of combination checkpoint blocking antibodies, with the highest reported benefit rate of any therapy for advanced melanoma and a very high rate of immune-related toxicitiesCrossRefPubMed
43.
Zurück zum Zitat Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–17.CrossRefPubMed Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–17.CrossRefPubMed
44.
Zurück zum Zitat Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park). 2014;28(Suppl 3):30–8. Review Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park). 2014;28(Suppl 3):30–8. Review
45.•
Zurück zum Zitat Robert C, Schadendorf D, Messina M, et al. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013;19:2232–9. Retreatment of relapse in previous ipilimumab responders without severe toxicity shows activity, supporting proof of the principle that unlike cytotoxic therapies, immunotherapy relapse does not always result from treatment-resistant tumor cells or immune-tumor interactions Robert C, Schadendorf D, Messina M, et al. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013;19:2232–9. Retreatment of relapse in previous ipilimumab responders without severe toxicity shows activity, supporting proof of the principle that unlike cytotoxic therapies, immunotherapy relapse does not always result from treatment-resistant tumor cells or immune-tumor interactions
46.•
Zurück zum Zitat Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19:462–8. Complements #48, in this report using PD-1 blockadeCrossRefPubMed Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19:462–8. Complements #48, in this report using PD-1 blockadeCrossRefPubMed
47.
Zurück zum Zitat Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.CrossRefPubMed Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.CrossRefPubMed
48.
Zurück zum Zitat Eggermont AM, Suciu S, Rutkowski P, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer. 2016;55:111–21.CrossRefPubMed Eggermont AM, Suciu S, Rutkowski P, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer. 2016;55:111–21.CrossRefPubMed
49.
Zurück zum Zitat Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30:3810–28.CrossRefPubMed Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30:3810–28.CrossRefPubMed
50.
Zurück zum Zitat Eggermont AM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012;48:218–25.CrossRefPubMed Eggermont AM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012;48:218–25.CrossRefPubMed
51.
Zurück zum Zitat Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30.CrossRefPubMed Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30.CrossRefPubMed
52.•
Zurück zum Zitat Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459–65. The first prospective clinical trial of CTLA4 blockade for melanoma metastatic to the brain, showing patient benefit in both the brain and extracranial compartment comparable to that of the same therapy for patients without brain metastasisCrossRefPubMed Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459–65. The first prospective clinical trial of CTLA4 blockade for melanoma metastatic to the brain, showing patient benefit in both the brain and extracranial compartment comparable to that of the same therapy for patients without brain metastasisCrossRefPubMed
53.
Zurück zum Zitat Cohen JV, Alomari AK, Vortmeyer AO et al. (2015) Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res Cohen JV, Alomari AK, Vortmeyer AO et al. (2015) Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res
54.
Zurück zum Zitat Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 2012;33:579–89.CrossRefPubMed Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 2012;33:579–89.CrossRefPubMed
55.
Zurück zum Zitat Ahmed KA, Stallworth DG, Kim Y et al. (2015) Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol Ahmed KA, Stallworth DG, Kim Y et al. (2015) Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol
56.•
Zurück zum Zitat Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84. First demonstration of activity and safety of nivolumab vs. chemotherapy in advanced melanoma patients previously treated with anti-CTLA-4 antibodyCrossRefPubMed Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84. First demonstration of activity and safety of nivolumab vs. chemotherapy in advanced melanoma patients previously treated with anti-CTLA-4 antibodyCrossRefPubMed
Metadaten
Titel
The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma
verfasst von
Kim Margolin, M.D.
Publikationsdatum
01.09.2016
Verlag
Springer US
Erschienen in
Current Treatment Options in Oncology / Ausgabe 9/2016
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-016-0421-5

Weitere Artikel der Ausgabe 9/2016

Current Treatment Options in Oncology 9/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.